Atreca Inc BCEL

Alternate Symbol(s): COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

PINL:BCEL - Post by User

Atreca Inc

Bullboard Posts

Comment by TheHoboon Dec 29, 2010 2:16pm

356 Views

Post# 17902676

RE: RE: RE: RE: remember

See how predictable you are? You can't even come up with an argument over the 1, 2, 3 year rates of return.. The core samples.. The technical analysis...

Can you hear the gasps of shock across the intarwebz? Ya me either. I guess I overestimated you as a short position holder; indeed you are just a mouth breather.

At least buy some chapstick, all that drool and air (and pole) crossing your lips has to be doing a real number on them.

Bullboard Posts

Amazon stock reaches for record highs after earnings report